CLAIMS

1. A controlled release oral solid pharmaceutical composition comprising a fumaric acid salt of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one as an active ingredient, and further comprising a cellulose-based water-soluble polymer,
wherein the composition is an osmotic pump composition, and the cellulose-based water-soluble polymer is at least one member selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, and methyl cellulose.

2. The composition according to claim 1, wherein the cellulose-based water-soluble polymer is contained in a drug layer.

3. The composition according to claim 2, wherein the drug layer comprises 1 to 35 mass% of the fumaric acid salt of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one based on the weight of the drug layer.

4. The composition according to claim 2 or 3, wherein the drug layer comprises
5 to 200 mg of the fumaric acid salt of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one in terms of the weight of the free base.

5. The composition according to any one of claims 2 to 4, wherein the drug layer comprises 5 to 40 mass% of a cellulose-based water-soluble polymer, based on the weight of the drug layer.

6. The composition according to any one of claims 1 to 5, wherein the fumaric acid salt of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one is present in an amount of 5 mg to 60 mg in terms of the weight of the free base.

7. The composition according to any one of claims 1 to 6 for use in preventing or treating a central nervous system (CNS) disease.

8. The composition according to claim 7 for use in preventing or treating a central nervous system (CNS) disease, wherein the composition is to be administered once a week at a dose of 5 mg to 60 mg in terms of the weight of the free base.

9. The composition according to claim 7 or 8 for use in preventing or treating a central nervous system (CNS) disease, wherein the composition is for preventing or treating a CNS disease selected from the group consisting of schizophrenia, treatment-resistant, refractory, or chronic schizophrenia, emotional disturbance, psychotic disorder, mood disorder, bipolar disorder, depression, endogenous depression, major depression, melancholic and treatment-resistant depression, dysthymic disorder, cyclothymic disorder, anxiety disorder, somatoform disorder, factitious disorder, dissociative disorder, sexual disorder, eating disorder, sleep disorder, adjustment disorder, substance-related disorder, anhedonia, delirium, cognitive impairment, cognitive impairment associated with neurodegenerative disease, cognitive impairment caused by neurodegenerative disease, cognitive impairment of schizophrenia, cognitive impairment caused by treatment-resistant, refractory, or chronic schizophrenia, vomiting, motion sickness, obesity, migraine, pain, mental retardation, autism disorder, Tourette's disorder, tic disorder, attention deficit hyperactivity disorder, conduct disorder, Down syndrome, impulsive symptoms associated with dementia, and borderline personality disorder.

10. Use of the composition according to any one of claims 1 to 6 in the manufacture of a medicament for the treatment of a central nervous system (CNS) disease.

11. The use according to claim 10, wherein the CNS disease is at least one selected from the group consisting of schizophrenia, treatment-resistant, refractory, or chronic schizophrenia, emotional disturbance, psychotic disorder, mood disorder, bipolar disorder, depression, endogenous depression, major depression, melancholic and treatment-resistant depression, dysthymic disorder, cyclothymic disorder, anxiety disorder, somatoform disorder, factitious disorder, dissociative disorder, sexual disorder, eating disorder, sleep disorder, adjustment

disorder, substance-related disorder, anhedonia, delirium, cognitive impairment, cognitive impairment associated with neurodegenerative disease, cognitive impairment caused by neurodegenerative disease, cognitive impairment of schizophrenia, cognitive impairment caused by treatment-resistant, refractory, or chronic schizophrenia, vomiting, motion sickness, obesity, migraine, pain, mental retardation, autism disorder, Tourette's disorder, tic disorder, attention deficit hyperactivity disorder, conduct disorder, Down syndrome, impulsive symptoms associated with dementia, and borderline personality disorder.